IL6 and rheumatoid arthritis: Furthermore, baricitinib treatment resulted in a significant reduction (P < 0.05) from baseline in plasma IL‐6 at week 12 in patients with active RA who had an inadequate response to methotrexate from a phase 2b (Tanaka et al, 2016), randomized, placebo‐controlled, dose‐ranging study (Fig 1B).